Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile
| Autor: | Miriam T. Levine, Karl Evans R. Henson, Eunice Ann H Wong, Donald P. Levine |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
medicine.drug_class Glycopeptide antibiotic Pharmacology medicine.disease_cause Microbiology Telavancin Vancomycin Virology Drug Resistance Bacterial medicine Humans Bacteria business.industry Teicoplanin Oritavancin Dalbavancin Bacterial Infections biochemical phenomena metabolism and nutrition Glycopeptide Anti-Bacterial Agents Infectious Diseases Staphylococcus aureus business medicine.drug |
| Zdroj: | Expert Review of Anti-infective Therapy. 13:1265-1278 |
| ISSN: | 1744-8336 1478-7210 |
| DOI: | 10.1586/14787210.2015.1068118 |
| Popis: | The first glycopeptide antibiotic was vancomycin, isolated from the soil in the 1950s; since then, the class has expanded to include teicoplanin and the new semisynthetic glycopeptides dalbavancin, oritavancin and telavancin. They are bactericidal, active against most Gram-positive organisms, and in a concentration-dependent manner, inhibit cell wall synthesis. Resistance to vancomycin has emerged, especially among enterococci and Staphylococcus aureus through a variety of mechanisms. This emerging resistance to vancomycin makes proper dosing and monitoring of the area under the curve/MIC critically important. The chief adverse effect of vancomycin is nephrotoxicity, which is also intricately related to its dose. The efficacy of the semisynthetic glycopeptides has been demonstrated in skin and soft-tissue infections, but remains to be seen in serious methicillin-resistant Staphylococcus aureus infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|